CVS Health (NYSE:CVS), a leading integrated healthcare and pharmacy solutions provider, released its fourth-quarter 2024 ...

Shareholders will be ecstatic, with their stake up 22% over the past week following CVS Health Corporation's (NYSE:CVS) ...

CVS Health stock received a positive adjustment to its Relative Strength (RS) Rating, from 70 to 73. Please watch the video ...

Sees FY25 free cash flow $6.5B. The company said, “The Company issued its full-year 2025 GAAP diluted EPS guidance range of $4.58 to $4.83 and ...

CVS Health posted Q4 sales of $97.71B, with a 23.3% rise in Health Care Benefits revenue. Fiscal 2025 adjusted EPS guidance ...

Retail pharmacy chain CVS Health (CVS) is scheduled to announce its results for the fourth quarter of 2024 before the market ...

Equities researchers at Leerink Partnrs increased their Q1 2025 earnings estimates for shares of CVS Health in a research report issued on Wednesday, February 12th. Leerink Partnrs analyst M. Cherny ...

Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

CVS Health's adjusted EPS outlook for 2025 reflects expectations of a meaningful recovery in Medicare Advantage and continued growth in Health Services. Today, CVS Health® (NYSE: CVS) named Ed ...

CVS Health's adjusted EPS beat estimates at $1.19, surpassing the expected $0.91. Revenue increased to $97.7 billion, exceeding expectations and reflecting a growth of 4.2% year-over-year.

Looking ahead, CVS Health's management forecasts an adjusted EPS range of $5.75 to $6.00 for 2025, expecting enhancements in financial results as value-based initiatives and digital investments ...